Jonathan J Keats
Overview
Explore the profile of Jonathan J Keats including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
4916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel D, Vij R, et al.
Nat Genet
. 2024 Aug;
56(9):1878-1889.
PMID: 39160255
Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking. The...
2.
Mouhieddine T, Nzerem C, Redd R, Dunford A, Leventhal M, Sklavenitis-Pistofidis R, et al.
Cancer Res Commun
. 2023 Nov;
3(12):2560-2571.
PMID: 38019104
Significance: Using our algorithm to differentiate tumor and germline mutations from CH mutations, we detected CH in approximately 10% of patients with newly diagnosed myeloma, including both transplant eligible and...
3.
Neri P, Barwick B, Jung D, Patton J, Maity R, Tagoug I, et al.
Blood Cancer Discov
. 2023 Nov;
5(1):56-73.
PMID: 37934799
Significance: We show that IKZF1-bound enhancers are critical for IMiD efficacy and that the factor ETV4 can bind the same enhancers and substitute for IKZF1 and mediate IMiD resistance by...
4.
Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al.
Nat Med
. 2023 Aug;
29(9):2295-2306.
PMID: 37653344
B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or...
5.
De Matos Simoes R, Shirasaki R, Downey-Kopyscinski S, Matthews G, Barwick B, Gupta V, et al.
Nat Cancer
. 2023 May;
4(5):754-773.
PMID: 37237081
Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has been driven by therapies that have limited applications beyond MM/PC neoplasias and do not target specific oncogenic...
6.
Davies F, Pawlyn C, Usmani S, San-Miguel J, Einsele H, Boyle E, et al.
Blood Cancer Discov
. 2022 Jun;
3(4):273-284.
PMID: 35653112
The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes,...
7.
Anderson G, Ballester-Beltran J, Giotopoulos G, Guerrero J, Surget S, Williamson J, et al.
Blood
. 2022 Feb;
139(16):2471-2482.
PMID: 35134130
The accessibility of cell surface proteins makes them tractable for targeting by cancer immunotherapy, but identifying suitable targets remains challenging. Here we describe plasma membrane profiling of primary human myeloma...
8.
Byron S, Hendricks W, Nagulapally A, Kraveka J, Ferguson W, Brown V, et al.
Cancer Res
. 2021 Oct;
81(23):5818-5832.
PMID: 34610968
Children with treatment-refractory or relapsed (R/R) tumors face poor prognoses. As the genomic underpinnings driving R/R disease are not well defined, we describe here the genomic and transcriptomic landscapes of...
9.
Gowin K, Skerget S, Keats J, Mikhael J, Cowan A
Leuk Res
. 2021 Aug;
111:106687.
PMID: 34425325
Plasma cell leukemia is a rare and aggressive plasma cell dyscrasia associated with dismal outcomes. It may arise de novo, primary plasma cell leukemia, or evolve from an antecedent diagnosis...
10.
Barwick B, Gupta V, Matulis S, Patton J, Powell D, Gu Y, et al.
Clin Cancer Res
. 2021 Mar;
27(11):3178-3189.
PMID: 33731366
Purpose: Multiple myeloma is a malignancy of plasma cells. Extensive genetic and transcriptional characterization of myeloma has identified subtypes with prognostic and therapeutic implications. In contrast, relatively little is known...